Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 113, Issue 11, Pages 1541-1547
Publisher
Springer Nature
Online
2015-11-11
DOI
10.1038/bjc.2015.373
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer
- (2014) S. Blagden et al. CLINICAL CANCER RESEARCH
- Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
- (2014) Jordi Rodon et al. INVESTIGATIONAL NEW DRUGS
- Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
- (2014) L Molife et al. Journal of Hematology & Oncology
- Metabolic complications with the use of mTOR inhibitors for cancer therapy
- (2013) Shanthi Sivendran et al. CANCER TREATMENT REVIEWS
- Duration of Rapamycin Treatment Has Differential Effects on Metabolism in Mice
- (2013) Yimin Fang et al. Cell Metabolism
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
- (2013) G. I. Shapiro et al. CLINICAL CANCER RESEARCH
- ENDOCRINE SIDE EFFECTS OF ANTI-CANCER DRUGS: Effects of anti-cancer targeted therapies on lipid and glucose metabolism
- (2013) Bruno Vergès et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience
- (2012) L. R. Molife et al. ANNALS OF ONCOLOGY
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Hepatic mTORC2 Activates Glycolysis and Lipogenesis through Akt, Glucokinase, and SREBP1c
- (2012) Asami Hagiwara et al. Cell Metabolism
- A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2012) D. S. Hong et al. CLINICAL CANCER RESEARCH
- Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
- (2012) Naifa L. Busaidy et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
- (2012) David Neal Franz et al. LANCET
- Endogenous viruses: insights into viral evolution and impact on host biology
- (2012) Cédric Feschotte et al. NATURE REVIEWS GENETICS
- Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
- (2012) D. W. Lamming et al. SCIENCE
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue
- (2010) V. P. Houde et al. DIABETES
- Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
- (2008) H-T Arkenau et al. BRITISH JOURNAL OF CANCER
- Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia
- (2008) M.-C. Crouthamel et al. CLINICAL CANCER RESEARCH
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now